Semaglutide is typically given once a week, while tirzepatide is also given as a weekly injection. Semaglutide has been shown to significantly lower HbA1c (a measure of long-term blood sugar control) and promote weight loss
Tirzepatide () Tirzepatide ()
The FDA prescribing information does not list hepatotoxicity as a known adverse effect, and extensive clinical trial data have not identified significant liver-related safety signals
At baseline, trained nurse interviewers administered a structured questionnaire to each subject to collect comprehensive information on demographics, occupation, lifestyle habits, medical history, usage of medication and dietary supplements, alcohol consumption, and past cigarette smoking history
The initial phase of tirzepatide treatment involves a gradual dose escalation protocol designed to minimize gastrointestinal side effects while allowing the body to adapt to the medication's effects
Exenatide can interfere with oral birth control